Sponsor content
270 result(s) found, displaying 1 to 10
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TREMFYA guselkumab 45 mg solution for injection pre-filled pen (VarioJect).
-
-
Jan-2026Prescription medicine evaluationActive ingredient: icotrokinra.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for RYBREVANT SC amivantamab 1600mg/10mL solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for RYBREVANT SC amivantamab 2240mg/14mL solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OPSUMIT macitentan 2.5 mg dispersible tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TREMFYA guselkumab 200 mg / 2 mL solution for injection, pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TREMFYA guselkumab 200 mg / 20 mL concentrated solution for intravenous infusion, vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TREMFYA guselkumab 200 mg / 2 mL solution for injection, pre-filled pen (auto-injector).
-
Australian public assessment report (AusPar)Lazcluze (lazertinib) in combination with amivantamab is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.